List of Trulance drug patents

Trulance is owned by Salix.

Trulance contains Plecanatide.

Trulance has a total of 10 drug patents out of which 2 drug patents have expired.

Expired drug patents of Trulance are:

  • US8637451
  • US7799897

Trulance was authorised for market use on 19 January, 2017.

Trulance is available in tablet;oral dosage forms.

Trulance can be used as irritable bowel syndrome with constipation; chronic idiopathic constipation, elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit, chronic idiopathic constipation; irritable bowel syndrome with constipation.

Drug patent challenges can be filed against Trulance from January, 2021.

The generics of Trulance are possible to be released after 05 June, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(7 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(4 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8637451 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Mar, 2022

(10 months ago)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use
Sep, 2031

(8 years from now)

US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(9 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in